SCHEMBL384900

SCHEMBL384900

C[C@@]1(CCc2ccco2)COC(=O)N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.39
MAPT P10636 5/20 0.37
RECQL P46063 3/20 0.37
TDP1 Q9NUW8 3/20 0.37
MEN1 O00255 2/20 0.37
POLB P06746 2/20 0.37
APEX1 P27695 2/20 0.37
KMT2A Q03164 2/20 0.37
DNMT1 P26358 2/20 0.37
HSD17B10 Q99714 2/20 0.37
PSMD14 O00487 1/20 0.37
MMP2 P08253 1/20 0.37
PTPN7 P35236 1/20 0.37
HBB P68871 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HPGD P15428 2/20 0.36
ALDH1A1 P00352 9/20 0.35
CYP2C19 P33261 2/20 0.35
USP2 O75604 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL383836 0.81 FPR2 (0.36) FPR2MAPTRECQLTDP1MEN1
SCHEMBL5166746 0.75 TAAR1 (0.39) FPR2MAPTMEN1KMT2AHSD17B10
SCHEMBL386428 0.74 IRAK4 (0.31) ALDH1A1IRAK4
SCHEMBL7614673 0.73 FPR2 (0.39) FPR2MAPTMEN1KMT2AALDH1A1
SCHEMBL7615636 0.72 S1PR1 (0.42) FPR2MAPTHSD17B10ALDH1A1KDM4E
SCHEMBL385654 0.72 RAB9A (0.35) MAPTRECQLMEN1POLBKMT2A
SCHEMBL385579 0.71 S1PR1 (0.30) IRAK4
SCHEMBL4462359 0.71 S1PR1 (0.33) HSD17B10IRAK4
SCHEMBL5165290 0.70 ALDH1A1 (0.33) TDP1L3MBTL1ALDH1A1KDM4EIRAK4
SCHEMBL5165572 0.70 TAAR1 (0.37) MAPTMEN1KMT2AHSD17B10KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101650-B2 Method for treating a immunology-related disease DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-24 US disclosed
US-8067396-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2011-11-29 US disclosed
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2010-02-11 US disclosed
US-20090326038-A1 Method for treating a immunology-related disease SANKYO COMPANY, LIMITED (JP) 2009-12-31 US disclosed
US-7638551-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2009-12-29 US disclosed
EP-1471054-B1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE DAIICHI SANKYO CO LTD (JP) 2009-07-01 EP disclosed
US-20070142335-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2007-06-21 US disclosed
US-20070105933-A1 Amino alcohol compounds SANKYO COMPANY, LIMITED (JP) 2007-05-10 US disclosed
US-7199150-B2 Amino alcohol compounds SANKYO COMPANY, LIMITED (JP) 2007-04-03 US disclosed
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these SANKYO COMPANY, LIMITED (JP) 2005-02-24 US disclosed
EP-1471054-A1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE Sankyo Company, Limited (JP) 2004-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these PHOSPHO1, CD4, FCGRT FPR2 654/4885MAPT 3715/4885RECQL 4130/4885
US-20090326038-A1 Method for treating a immunology-related disease C3AR1, HRH3, HRH2 FPR2 33/4885MAPT 3338/4885RECQL 3402/4885
US-20070105933-A1 Amino alcohol compounds ADH1C, C9, SSB FPR2 25/4885MAPT 2117/4885RECQL 4592/4885
US-20070142335-A1 Amino alcohol compounds or phosphonic acid derivatives thereof HRH3, C3AR1, HRH4 FPR2 44/4885MAPT 1819/4885RECQL 4695/4885
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof PHOSPHO1, ADH1C, ADH1A FPR2 621/4885MAPT 3634/4885RECQL 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.